Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Shire sits in the top decile of US sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count).
Shire: 245 sponsored US clinical trials, 1 recruiting.
Shire sponsors 245 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 212 completed. 118 of these trials are in Phase 3-4 (later-stage) and 108 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 6 trials.
Top-decile sponsor footprint
Shire ranks in the top decile of sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
212 of 242 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
245 total, page 5 of 5
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT00500149
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
NCT00446849
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
NCT00457015
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
NCT00456508
Long-term Effect of Lanthanum Carbonate on Bone
NCT00557323
Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers
NCT00399308
Head to Head Study Against Sevelamer Hydrochloride
NCT00441545
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
NCT00411645
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
NCT00367835
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
NCT00432510
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
NCT00438815
A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide
NCT00820885
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
NCT00462709
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
NCT00567723
Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease
NCT00234702
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
NCT00262080
Hunter Outcome Survey (HOS)
NCT03292887
Safety and Efficacy of SPD465 in Adults With ADHD
NCT00202605
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
NCT00151892
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
NCT00289211
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
NCT01005888
Open Label Extension
NCT00172120
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
NCT00172185
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
NCT00097695
Maribavir for Prevention of CMV After Stem Cell Transplants
NCT00223925
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
NCT00630747
Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
NCT00555880
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
NCT00084084
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
NCT00081458
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008
NCT00308438
ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD
NCT00557960
Calcium Supplementation in Postmenopausal Women
NCT00172172
Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches
NCT00172094
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
NCT00072839
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
NCT00503243
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
NCT00069641
Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD
NCT00506727
Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00507065
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
NCT00046163
Open Label Extension Study of PREOS
NCT00172133
Fabry Outcome Survey (FOS)
NCT03289065
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00012259
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
NCT00172081
A Study for Patients With Neurogenic Orthostatic Hypotension
NCT00046475
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
NCT00172107
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 56 |
| Phase 3 | 98 |
| Phase 4 | 20 |
What is open in the Shire pipeline
1 recruiting of 245 indexed (0% open); 212 completed (87%).
Phase mix: 118 late (III/IV) vs 108 early (I/II) (balanced across stages).
Top condition: Healthy (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shire: open-pipeline peers nationwide
Peers matched on 245 registered trials and 0% open enrollment, not the therapeutic-area sidebar.
Shire sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 245 trials (± recruiting share)
- University of Cincinnati · 245 trials · 14% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
- Masonic Cancer Center, University of Minnesota · 249 trials · 14% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 0% open enrollment (± trial volume)
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- 10xBio · 0% recruiting · 3 trials
Related
What to do with this Shire page
245 registered trials is a research-attention snapshot, not an endorsement of Shire or any single study.
- 1 of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shire pipeline card: 245 registered trials from official public datasets.Report a data error.